Haitong Securities Co., Ltd

About Shanghai Junshi Biomedical Technology Co., Ltd

2024 Annual Continuous Supervision On-site Inspection Report

Shanghai Stock Exchange:

Shanghai Junshi Biomedical Technology Co., Ltd. (hereinafter referred to as "Junshi Biosciences", "listed company", "the company") was approved by the China Securities Regulatory Commission (CSRC) for the first time in the "Reply on Agreeing to the Registration of the Initial Public Offering of Shares of Shanghai Junshi Biomedical Technology Co., Ltd." (Zheng Jian Xu Xu [2020] No. 940).

87.13 million shares were issued to the public, with a par value of RMB 1 per share and an issue price of RMB 55.50 per share

The total amount of funds raised was RMB4,835,715,000.00, and the actual net amount of funds raised was RMB4,496,978,326.73 after deducting the issuance expenses. The above-mentioned funds have all been in place, and Rongcheng Certified Public Accountants (Special General Partnership) has verified the funds in place for the company's public offering of new shares

On July 8, 2020, Rong Cheng Yan Zi [2020] No. 230Z0103 "Capital Verification Report" was issued. Initial Public Offerings

The securities were listed on the Shanghai Stock Exchange on July 15, 2020. Haitong Securities Co., Ltd. (with

hereinafter referred to as the "Sponsor Institution" or "Haitong Securities") acts as its ongoing supervising sponsor.

With the approval of the China Securities Regulatory Commission's "Reply on Agreeing to the Registration of Shanghai Junshi Biomedical Technology Co., Ltd.'s Issuance of Shares to Specific Targets" (Zheng Jian Xu Xu [2022] No. 2616), Junshi Biosciences issued 70 million shares to specific targets, with a par value of RMB 1 per share and an issue price of RMB 53.95 per share, raising a total of RMB 3,776,500,000.00, after deducting the issuance expenses

The net proceeds amounted to RMB3,744,802,794.94. The offering of securities was made in December 2022

Listed on the Shanghai Stock Exchange on the 2nd. Haitong Securities acted as its continuous supervision sponsor for the period of continuous supervision

From December 2, 2022 to December 31, 2024.

In accordance with the Administrative Measures for the Sponsorship Business of Securities Issuance and Listing, the Rules for the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange, the Self-Regulatory Guidelines for Listed Companies on the Shanghai Stock Exchange No. 11 - Continuous Supervision, and the Self-Regulatory Guidelines for Listed Companies on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operation

Requirements, Haitong Securities as a continuous supervision sponsor, March 17, 2025, March 20, 2025

On March 21, 2025, an on-site inspection was conducted on Junshi Biosciences, and the situation of this on-site inspection is now present

The report is as follows:

1. The basic situation of this on-site inspection

(1) Sponsors

Haitong Securities Co., Ltd

(2) Sponsor representatives

Cui Hao, Chen Xinjun

(3) On-site inspection time

March 17, 2025, March 20, 2025 and March 21, 2025

(4) On-site inspection personnel

Cui Hao, Chen Xinjun, Shao Yang, Jiang Haoming

(5) On-site inspection methods

1. Interview and communicate with relevant directors, supervisors, senior managers and relevant personnel of the company;

2. Check the company's production and operation sites;

3. Check the documents of the company's three meetings held since 2024;

4. Check the company's regular reports, temporary announcements and other information disclosure documents since 2024;

5. Check the bank statement of the company's special account for raising funds, major contracts and vouchers related to the use of raised funds;

6. Check the company's internal control system documents;

7. Check the company's related party transactions, external guarantees and major foreign investments since 2024.

2. Opinions on on-site inspection items item by item

(1) Corporate governance and internal control

The sponsor reviewed the company's articles of association, the rules of procedure of the board of directors, the board of supervisors, the general meeting of shareholders and other internal control systems, the meeting documents of the general meeting of shareholders, the board of directors, the board of supervisors and special committees since 2024, and interviewed and communicated with the relevant directors, supervisors, senior management and relevant personnel of the company.

After verification, the sponsor believes that as of the date of issuance of this report, the company has established a standardized corporate governance structure that meets the requirements of listed companies in accordance with the requirements of laws, regulations and normative documents such as the Company Law and the Securities Law, and the Articles of Association, the Rules of Procedure of the General Meeting of Shareholders, the Rules of Procedure of the Board of Directors and the Rules of Procedure of the Board of Supervisors can be effectively implemented, and the directors, supervisors and senior managers of the Company shall perform their duties in accordance with the relevant laws and regulations and the business rules of the Shanghai Stock Exchange. The corporate governance mechanism has worked effectively; The company's internal organization and distribution of rights and responsibilities are reasonable, and the business authority, approval procedures, and corresponding responsibilities of each department and position are clearly compliant and can be effectively implemented; The company has established an internal audit system, the internal audit department and the audit committee of the board of directors constitute and perform their duties in compliance, and the company's internal control system has been effectively implemented; Since 2024, the convening, convening and voting procedures of the company's three meetings have been legal and compliant, the meeting records are complete, the meeting materials are well preserved, and the meeting resolutions have been signed and confirmed by the directors or supervisors attending the meeting.

(2) Information disclosure

The sponsor reviewed the company's information disclosure system, the company's disclosed announcements since 2024, and the relevant documents

and interview and communicate with the company's relevant directors, supervisors, senior management and relevant personnel.

After verification, the sponsor believes that as of the date of issuance of this report, the company has formulated a complete information disclosure system, which complies with the relevant laws and regulations such as the Administrative Measures for Information Disclosure of Listed Companies and the Listing Rules of the Science and Technology Innovation Board of the Shanghai Stock Exchange, and the company has fulfilled the necessary information disclosure obligations, and there are no false records, misleading statements and material omissions in information disclosure.

(3) The independence of the company and the capital transactions with the controlling shareholder, actual controller and other related parties

The sponsor has consulted the articles of association, related party transaction management system and other relevant institutional documents, since 2024

I came to the documents and announcements of the three meetings, reviewed the relevant information of the company's transactions and transactions with related parties, and interviewed and communicated with the company's relevant directors, supervisors, senior managers and relevant personnel.

After verification, the sponsor believes that as of the date of this report, the company's assets are complete since 2024,

The personnel, finance, institutions and business are independent, and there is no illegal occupation of the company's funds by the controlling shareholder, actual controller and other related parties.

(4) The use of raised funds

The sponsor institution consults the company's fund-raising management system and other relevant system documents, and has been related to the fundraising since 2024

The documents and announcements related to the use of funds, the bank statements of the special account for raising funds, major contracts, vouchers and other materials related to the use of raised funds, and interviews and communication with relevant directors, supervisors, senior managers and relevant personnel of the company.

After verification, the sponsor believes that as of the date of issuance of this report, the company has established a management system for raised funds, and can store and use the raised funds in accordance with the provisions of the system, and the company has performed the relevant decision-making procedures and disclosed information in accordance with the provisions of the raised funds, and there is no illegal use of raised funds.

(5) Related party transactions, external guarantees, and major foreign investments

The sponsor reviewed the company's articles of association, related party transactions, external guarantees, foreign investment and other internal control systems, the company's internal decision-making documents, major contracts, announcements and other materials related to related party transactions, external guarantees and major foreign investments since 2024, and interviewed and communicated with the company's relevant directors, supervisors, senior management and relevant personnel.

After verification, the sponsor believes that as of the date of this report, there has been no violation of the company since 2024

Regulate related party transactions, external guarantees and major foreign investments.

(6) Business conditions

The sponsor reviewed the company's financial reports and related financial and business information, as well as the financial reports of listed companies in the same industry, and interviewed and communicated with the company's relevant directors, supervisors, senior managers and relevant personnel.

After verification, the sponsor believes that as of the date of issuance of this report, the company's operating conditions are good, the business operation is normal, and the business model of the main business has not undergone major changes. The market prospects of the company's main business and the operating environment of the industry have not undergone major adverse changes.

(7) Other matters that the sponsor deems necessary to be inspected on site

Not.

3. Matters and suggestions for the attention of listed companies

Not.

4. Whether there are any matters that should be reported to the China Securities Regulatory Commission and the Shanghai Stock Exchange in the Administrative Measures for the Sponsorship Business of Securities Issuance and Listing and the relevant regulations of the Shanghai Stock Exchange

Since 2024, the Company has not existed in the Administrative Measures for the Sponsorship Business of Securities Issuance and Listing and Shanghai Securities

Matters that shall be reported to the China Securities Regulatory Commission and the Shanghai Stock Exchange in accordance with the relevant regulations of the Exchange.

5. Cooperation of listed companies and other intermediaries

During the on-site inspection of the sponsor institution, the company and other intermediaries gave active cooperation and provided necessary support for the on-site inspection.

6. The conclusion of this on-site inspection

After on-site inspection, the sponsor believes that since 2024, Junshi Biosciences has been in corporate governance and internal control

The operation of the three committees, information disclosure, independence, use of raised funds, related party transactions, external guarantees, major foreign investments, investor protection and other important aspects of the operation comply with the relevant requirements of the "Rules for the Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange", "Self-Regulatory Guidelines for Listed Companies on the Shanghai Stock Exchange No. 11 - Continuous Supervision", "Self-Regulatory Guidelines for Listed Companies on the Science and Technology Innovation Board of the Shanghai Stock Exchange No. 1 - Standardized Operation", etc., as of the date of this report, the company's operating conditions are good. There have been no significant changes in business operations.

(No text below)

(There is no text on this page, it is the signed and stamped page of the "Haitong Securities Co., Ltd. on the 2024 Continuous Supervision and On-site Inspection Report of Shanghai Junshi Biomedical Technology Co., Ltd.")

Signature of the Sponsor Representative:

Cui Hao, Chen Xinjun

Haitong Securities Co., Ltd

date